{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-080081","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.724534+00:00","generated_at":"2026-06-26T21:25:15.776906+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"UroGen Pharma CFO resigns; reports FY2021 Jelmyto revenue $48M, net loss $110.8M","bullets":["CFO Molly Henderson resigns effective March 25, 2022; replaced by Dong Kim (VP Finance).","FY2021 Jelmyto net product revenue $48.0M, up 307% YoY; Q4 revenue $16.2M, up 42% QoQ.","FY2021 net loss $110.8M ($4.96/share) vs $128.5M loss in prior year.","2022 revenue guidance $70-80M; operating expenses guided $140-160M; RTW financing expense $22-26M.","Closed $75M tranche of up to $100M senior secured term loan facility with Pharmakon Advisors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-080081","json":"https://secwatch.observer/filing/0001193125-22-080081.json","markdown":"https://secwatch.observer/filing/0001193125-22-080081.md","text":"https://secwatch.observer/filing/0001193125-22-080081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/0001193125-22-080081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/d258593d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:25:15.776906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e0ed7a4066","claim":"Dong (Don) Kim was appointed as Chief Financial Officer at UroGen Pharma Ltd..","evidence_excerpt":"Effective as of March 25, 2022 (the “Effective Date”), the Company appointed Dong (Don) Kim as Chief Financial Officer of the Company, as well as the Company’s principal financial officer and principal accounting officer, replacing Ms. Henderson in such capacities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/0001193125-22-080081-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ea998af7ca","claim":"Molly Henderson resigned as Chief Financial Officer at UroGen Pharma Ltd..","evidence_excerpt":"On March 17, 2022, Molly Henderson tendered her resignation as the Company’s Chief Financial Officer, effective March 25, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/0001193125-22-080081-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}